Skip to main content

Paraneoplastic Neurological Syndromes

  • Chapter
  • 1372 Accesses

Abstract

Paraneoplastic neurological syndromes are caused by the remote, nonmetastatic effect of malignancies.

The prognosis of individual paraneoplastic neurological diseases varies considerably. In forms involving antibodies against neuronal surface antigens, tumor removal and immunosuppressive treatment can lead to complete recovery. Fifty percent of patients with paraneoplastic encephalomyelitis, sensory neuronopathy, paraneoplastic cerebellar degeneration, and Lambert-Eaton syndrome survive 2 years after the onset.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349(16):1543–54.

    Article  CAS  PubMed  Google Scholar 

  2. Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098–107.

    Article  PubMed  Google Scholar 

  3. Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol. 2010;67(3):330–5.

    Article  PubMed  Google Scholar 

  4. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain. 2010;133(9):2734–48.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumors in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011;18(1):19–e3.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Vedeler CA, Antoine JC, Giometto B, et al. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol. 2006;13(7):682–90.

    Article  CAS  PubMed  Google Scholar 

  7. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157–65.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bruno Giometto .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Italia

About this chapter

Cite this chapter

Zoccarato, M., Zuliani, L., Giometto, B. (2015). Paraneoplastic Neurological Syndromes. In: Sghirlanzoni, A., Lauria, G., Chiapparini, L. (eds) Prognosis of Neurological Diseases. Springer, Milano. https://doi.org/10.1007/978-88-470-5755-5_27

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-5755-5_27

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-5754-8

  • Online ISBN: 978-88-470-5755-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics